Hyperkalemia alters endothelium-dependent relaxation through non-nitric oxide and noncyclooxygenase pathway: A mechanism for coronary dysfunction due to cardioplegia

Annals of Thoracic Surgery

Volumn 61, Issue 5, 1996, Pages 1394-1399

  He, Guo Wei ^a   Yang, Cheng Qin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

ANIMAL TISSUE; ARTICLE; CARDIOPLEGIA; COMPLICATION; CORONARY ARTERY DISEASE; ETIOLOGY; HYPERKALEMIA; NONHUMAN; PRIORITY JOURNAL; SWINE;

EID: 0030005864     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(96)00086-0     Document Type: Article

References (24)

1. Saldanha C, Hearse DJ. Coronary vascular responsiveness to 5-hydroxytryptamine before and after infusion of hyperkalemic crystalloid cardioplegic solution in the rat heart. Possible evidence of endothelial damage. J Thorac Cardiovasc Surg 1989;98:783-7.
2. Evora PRB, Pearson PJ, Schaff HV. Crystalloid cardioplegia and hypothermia do not impair endothelium-dependent relaxation or damage vascular smooth muscle of epicardial coronary arteries. J Thorac Cardiovasc Surg 1992;104: 1365-74.
3. He G-W, Yang C-Q, Wilson GJ, Rebeyka IM. Tolerance of coronary endothelium and smooth muscle to hyperkalemia. Ann Thorac Surg 1994;57:682-8.
4. He G-W, Yang C-Q, Rebeyka IM, Wilson GJ. Effect of neonatal endothelium and smooth muscle to hyperkalemic cardioplegic solutions. J Heart Lung Transplant 1995;14:92-101.
5. Nilsson FN, Miller VM, Vanhoutte PM, McGregor CGA. Methods of cardiac preservation alter the function of the endothelium in porcine coronary arteries. J Thorac Cardiovasc Surg 1991;102:923-30.
6. 2+ entry in human and bovine endothelial cells. J Physiol 1995;482:259-74.
7. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol 1988;93:515-24.
8. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol 1988;95:1165-74.
9. Taylor SG, Weston AH. Endothelium-derived hyperpolarizing factor: a new endogenous inhibitor from the vascular endothelium. Trends Pharmacol Sci 1988;9:72-4.
10. Nagao T, Vanhoutte PM. Hyperpolarization contributes to endothelium-dependent relaxations to acetylcholine in femoral veins of rats. Am J Physiol 1991;261(Heart Circ Physiol 30):H1034-7.
11. Chen G, Yamamoto Y, Miwa K, Suzuki H. Hyperpolarization of arterial smooth muscle induced by endothelial humoral substances. Am J Physiol 1991;260(Heart Circ Physiol 29): H1888-92.
12. Holzmann S, Kukovetz WR, Windischhofer W, Paschke E, Graier WF. Pharmacologic differentiation between endothelium-dependent relaxations sensitive and resistant to nitroL-arginine in coronary arteries. J Cardiovasc Pharmacol 1994;23:747-56.
13. Brayden JE. Membrane hyperpolarization is a mechanism of endothelium-dependent cerebral vasodilation. Am J Physiol 1990;259(Heart Circ Physiol 28):H668-73.
14. He G-W, Angus JA, Rosenfeldt FL. Reactivity of the canine isolated internal mammary artery, saphenous vein, and coronary artery to constrictor and dilator substances: relevance to coronary bypass graft surgery. J Cardiovasc Pharmacol 1988;12:12-22.
15. 1-adrenoceptor mediated contraction in the human internal mammary artery. J Cardiovasc Pharmacol 1993;21:256-63.
16. He G-W, Buxton B, Rosenfeldt F, Angus JA. Reactivity of human isolated internal mammary artery to constrictor and dilator agents. Implications for treatment of internal mammary artery spasm. Circulation 1989;80(Suppl 1):141-50.
17. Siegel G, Walter A, Schnalke F, et al. Potassium channel activation, hyperpolarization, and vascular relaxation. Z Kardiol 1991;80(Suppl 7):9-24.
18. Yeh T Jr, Hanan SA, Johnson DE, et al. Superior myocardial preservation with modified UW solution after prolonged ischemia in the rat heart. Ann Thorac Surg 1990;49:932-9.
19. Stein DG, Permut LC, Drinkwater DC Jr, et al. Complete functional recovery after 24-hour heart preservation with university of Wisconsin solution and modified reperfusion. Circulation 1991;84(Suppl 3)316-23.
20. Jeevanandam V, Auteri JS, Sanchez JA, et al. Improved heart preservation with University of Wisconsin solution: experimental and preliminary human experience. Circulation 1991; 84(Suppl 3):324-8.
21. Jeevanandam V, Barr ML, Auteri JS, et al. University of Wisconsin solution versus crystalloid cardioplegia for human donor heart preservation. A randomized blinded prospective clinical trial. J Thorac Cardiovasc Surg 1992;103: 194-9.
22. Aeba R, Keenan RJ, Hardesty RL, Yousem SA, Hamamoto I, Griffith BP. University of Wisconsin solution for pulmonary preservation in a rat transplant model. Ann Thorac Surg 1992;53:240-6.
23. Keshavjee SH, Yamazaki F, Cardoso PF, McRitchie DI, Patterson GA, Cooper JD. A method for safe twelve-hour pulmonary preservation. J Thorac Cardiovasc Surg 1989;98: 529-34.
24. Sato H, Zhao ZQ, McGee DS, Williams MW, Hammon JW Jr, Vinten-Johansen J. Supplemental L-arginine during cardioplegic arrest and reperfusion avoids regional postischemic injury. J Thorac Cardiovasc Surg 1995;110:302-14.